Wilson's Disease
Wilson's disease is an autosomal recessive disorder of copper metabolism caused by mutations in the ATP7B gene, leading to toxic copper accumulation in the liver, brain, and other organs.
Wilson's Disease
Wilson's disease (also known as hepatolenticular degeneration) is a genetic disorder of copper metabolism inherited in an autosomal recessive (AR) manner, caused by mutations in the ATP7B gene on chromosome 13 [1][2][3]. The name breaks down neatly: "hepato-" = liver, "lenticular" = lentiform nucleus (part of the basal ganglia), "degeneration" = progressive damage — telling you the two principal targets of the disease.
The core defect is impairment of cellular copper (Cu²⁺) transport, resulting in a defective protein that fails in copper incorporation into ceruloplasmin and biliary copper excretion, leading to accumulation of copper in several organs, most notably the liver, brain, and cornea [2][4].
| Parameter | Detail |
|---|---|
| Prevalence | 1 in 30,000 live births in most populations [2][3] (Adrian Lui Paeds notes cite 1/200k — this likely refers to clinical prevalence vs genetic carrier prevalence) |
| Sex ratio | M:F ≈ 1:1 [2][3] |
| Female predominance in ALF | Females are more likely to develop acute liver failure (M:F = 1:4 for ALF specifically) [4] |
| Age at diagnosis | Mean age 12–23 years; majority diagnosed between 5–35 years [4] |
| Average onset | ~13 years [1] |
| Carrier frequency | ~1 in 90 (AR inheritance) |
| Genetic vs clinical prevalence | Incomplete penetrance — genetic prevalence >> clinical prevalence [1][2] |
Key epidemiological points to understand:
- Children are more likely to present with hepatic manifestations [4]
- Older patients (adolescents/young adults) are more likely to present with neurological manifestations [4]
- This makes sense because copper accumulates in the liver first (from birth), and only once hepatocytes are damaged and release copper into the bloodstream does extrahepatic deposition (brain, cornea, kidneys) occur
Hong Kong Context
- While Wilson's disease is rare globally, Hong Kong has a significant proportion of patients with chronic liver disease from HBV — Wilson's disease must be actively excluded in young patients with unexplained liver disease to avoid missing this treatable condition
- The ATP7B mutation spectrum in Chinese/East Asian populations differs from European populations (most common mutation in Europeans is H1069Q; in East Asians it is R778L) [2]
Wilson's disease is a monogenic disorder, so "risk factors" in the traditional sense do not apply. However:
- Family history — AR inheritance; siblings of an affected individual have a 25% chance of being affected
- Consanguinity — increases homozygosity risk
- Ethnicity — certain populations have higher carrier frequencies
- Children diagnosed through family screening because of an affected sibling are often asymptomatic [4]
Anatomy and Normal Copper Physiology
To understand Wilson's disease, you must understand how copper is normally handled:
- Dietary intake: ~2–5 mg/day from food (shellfish, nuts, chocolate, liver, mushrooms)
- Absorption: Duodenum and proximal jejunum via copper transporter 1 (CTR1)
- Portal circulation: Copper travels to the liver bound to albumin and histidine
- Hepatocyte uptake: Copper enters hepatocytes via CTR1
- Intracellular handling:
- Copper is bound by metallochaperones (e.g., ATOX1) which deliver it to specific compartments
- ATOX1 delivers copper to ATP7B in the trans-Golgi network
- ATP7B functions (the critical protein):
- Ceruloplasmin: A copper-containing α2-globulin with ferroxidase activity (oxidises Fe²⁺ to Fe³⁺); carries ~90% of circulating copper
- Biliary excretion: ~0.5–1.5 mg/day — matches dietary absorption to maintain copper balance
| Organ | Anatomical target | Why it matters |
|---|---|---|
| Liver | Hepatocytes | First site of copper accumulation (ATP7B is mainly expressed in liver) [2] |
| Brain | Basal ganglia (lentiform nucleus = putamen + globus pallidus), cerebellum, brainstem | Extrapyramidal motor symptoms |
| Eyes | Descemet's membrane (cornea), lens | Kayser-Fleischer rings, sunflower cataracts |
| Kidneys | Proximal tubules | Fanconi syndrome |
| Blood | Red blood cells | Haemolytic anaemia |
| Joints | Articular cartilage | Arthropathy, chondrocalcinosis |
| Heart | Myocardium | Cardiomyopathy (rare) |
Aetiology and Pathophysiology
- ATP7B gene on chromosome 13 encodes a copper-transporting P-type ATPase (the "Wilson disease protein") [1][2][3][4]
- The "P-type ATPase" means it uses ATP hydrolysis to pump copper across membranes (the "P" stands for phosphorylation of the enzyme during the transport cycle)
- > 200 different mutations identified [1][2]
- Most cases are compound heterozygotes [1][2][4] — meaning patients carry two different mutations in ATP7B, one on each chromosome 13
- This is why genetic testing does not have to be positive to reach a diagnosis — the hereditary pathway of Wilson's is very heterogeneous; not just one ATP7B mutation [7]
- A negative genetic test does NOT exclude Wilson's disease if clinical and biochemical features are compatible
Compound Heterozygosity – Exam Concept
Compound heterozygotes = having 2 heterozygous recessive alleles at a particular locus that cause genetic disease in a heterozygous state. Identification of two mutations on opposite chromosomes, both heterozygous recessive alleles affecting the same gene ATP7B [4]. This explains why genetic testing can be challenging — you need to find BOTH mutations, and many are private/rare.
Let me walk through this:
-
Mutation of ATP7B results in impaired incorporation of copper into apoceruloplasmin [2]
-
Defective Cu excretion into bile → accumulates inside liver causing damage (↑ hepatic Cu) [3]
- Since biliary excretion is the ONLY significant exit route for copper, this is catastrophic
- Copper accumulation within hepatocytes occurs gradually since birth [1]
-
Damaged hepatocytes release stored Cu in free form → ↑ serum free Cu, ↑ 24h urine Cu [3]
- The distinction between free (non-ceruloplasmin-bound) copper and total copper is critical
- Total serum copper is actually LOW (because ceruloplasmin-bound copper is reduced)
- But FREE copper is HIGH (because damaged hepatocytes dump unbound copper)
-
↑ Free serum copper concentration → extrahepatic copper deposition, especially the brain, kidney, cornea [1]
Why Liver First, Brain Later?
The liver is affected first because ATP7B is mainly expressed there — copper accumulates in hepatocytes from birth. Neurological manifestations come later because they depend on copper being RELEASED from damaged hepatocytes into the circulation, which then deposits in the brain. This is why children present with liver disease and older patients present with neurological features [4].
Pathophysiology of Specific Organ Damage
- Direct copper toxicity to hepatocytes:
- Oxidative stress: Free copper catalyses Fenton-like reactions → reactive oxygen species (ROS) → lipid peroxidation → membrane damage
- Mitochondrial dysfunction: Copper accumulates in mitochondria → impaired oxidative phosphorylation
- Apoptosis and necrosis: Progressive hepatocyte death
- Spectrum: steatosis → chronic hepatitis → fibrosis → cirrhosis → acute liver failure
- Copper deposits predominantly in the basal ganglia (especially putamen and caudate), cerebellum, and brainstem
- Mechanism: copper-induced oxidative damage to neurons, demyelination, astrocyte swelling (Alzheimer type II astrocytosis)
- Can mimic Parkinson's disease — extrapyramidal deposition of copper [7]
- Copper deposits in Descemet's membrane of the cornea [3]
- Descemet's membrane is the basement membrane of corneal endothelium — it preferentially binds copper due to its sulfur-rich composition
- Appears as a golden-brown ring at the limbus (junction of cornea and sclera), best seen on slit-lamp examination
- Copper deposits in proximal tubules → tubular dysfunction → Fanconi syndrome
- Fanconi syndrome = generalised proximal tubule transport defect → aminoaciduria, glycosuria (normoglycaemic), phosphaturia, bicarbonaturia (type 2 RTA), uricosuria
- Coombs-negative haemolytic anaemia [3][7]
- Mechanism: copper released from damaged hepatocytes deposits in RBC membranes → oxidative damage → intravascular haemolysis
- Coombs negative because this is NOT immune-mediated — it's direct toxicity
- Fulminant hepatic failure due to Wilson's has a very specific feature: young patients with no reason for fulminant liver failure, exclusion of all other common causes → only finding is low haemoglobin → Coombs-negative haemolytic anaemia [7]
Classification
Wilson's disease can be classified by mode of presentation:
| Type | Typical Age | Features |
|---|---|---|
| Hepatic | Children, early adolescence | Acute hepatitis, chronic hepatitis, cirrhosis, acute liver failure |
| Neurological | Late adolescence, young adults | Extrapyramidal symptoms, cerebellar signs, psychiatric |
| Mixed | Variable | Both hepatic and neurological |
| Other | Variable | Renal, haematological, musculoskeletal, cardiac |
- Acute hepatitis — clinically indistinguishable from acute viral hepatitis
- Chronic hepatitis — often asymptomatic, chronically elevated ALT/AST
- Cirrhosis — present in ~35–45% of patients at time of diagnosis [1]
- Fulminant hepatic failure (8–12%) — may be associated with massive release of free copper into bloodstream [1]
The Leipzig score is the standardised diagnostic scoring system for Wilson's disease, incorporating clinical, biochemical, and genetic parameters [3]. (Detailed in the diagnostic criteria section to follow.)
Clinical Features
Symptoms
The liver is the first organ affected [1][4].
| Symptom | Pathophysiological Basis |
|---|---|
| Jaundice | Hepatocyte damage → impaired bilirubin conjugation and excretion; in acute liver failure, massive hepatocyte necrosis releases unconjugated and conjugated bilirubin |
| Abdominal pain (RUQ) | Hepatic inflammation → Glisson's capsule distension (the liver parenchyma itself has no pain fibres; pain comes from the capsule) |
| Fatigue, malaise | Impaired hepatic synthetic and metabolic function → accumulation of toxins, reduced energy substrate processing |
| Anorexia, nausea | Hepatic inflammation, portal hypertension → gastric/intestinal congestion |
| Easy bruising/bleeding | Impaired hepatic synthesis of coagulation factors (II, VII, IX, X) and reduced thrombopoietin → thrombocytopenia (also from hypersplenism) |
| Abdominal distension | Ascites from portal hypertension (↑ hydrostatic pressure in splanchnic bed + ↓ albumin → ↓ oncotic pressure) |
| Leg swelling | Hypoalbuminaemia → reduced plasma oncotic pressure; also from portal hypertension-related fluid retention |
Hepatic presentations include: persistently elevated serum aminotransferases, chronic hepatitis, cirrhosis, fulminant hepatic failure [8]
Neurological presentations are due to copper deposition in the basal ganglia, cerebellum, and brainstem [1][8].
| Symptom | Pathophysiological Basis |
|---|---|
| Dysarthria (85–97%) | Cerebellar and/or extrapyramidal dysfunction → poor coordination of speech muscles; can be ataxic, athetoid, hypophonic, or spastic [1] |
| Tremor | Basal ganglia copper deposition → disruption of normal motor circuits; classically "wing-beating tremor" = coarse, irregular, proximal arm tremor (arms outstretched, like a bird flapping wings) — this is a postural/kinetic tremor from cerebellar involvement [3][8] |
| Dystonia (11–69%) | Basal ganglia damage → sustained involuntary muscle contractions; can include blepharospasm (involuntary eyelid closure), torticollis [1] |
| Gait abnormalities and ataxia (30–75%) | Cerebellar involvement → wide-based, uncoordinated gait [1] |
| Choreiform movements | Basal ganglia (caudate/putamen) damage → loss of normal movement suppression → involuntary, irregular, flowing movements [8] |
| Parkinsonism | Copper deposition in basal ganglia can mimic Parkinson's disease [7][8] → bradykinesia, rigidity, rest tremor |
| Pseudobulbar palsy | Bilateral upper motor neuron lesions to brainstem nuclei → dysphagia, emotional lability, brisk jaw jerk [8] |
| Seizures | Cortical copper deposition → neuronal hyperexcitability [8] |
| Drooling | Dysphagia + poor oropharyngeal coordination from extrapyramidal/bulbar dysfunction |
| Difficulty writing | Fine motor dysfunction from extrapyramidal and/or cerebellar involvement |
Wilson's Disease in the DDx of Movement Disorders
Wilson's disease must always be in the differential for secondary (symptomatic) parkinsonism in young patients [9]. It is also a cause of dystonia, chorea, and cerebellar ataxia in young adults. The key teaching point: always check ceruloplasmin and copper studies in any young patient with unexplained movement disorder.
Psychiatric manifestations can precede or accompany neurological features and are due to copper deposition in the cerebral cortex and limbic system [8].
| Symptom | Pathophysiological Basis |
|---|---|
| Depression | Frontal lobe and limbic copper deposition → disruption of serotonergic/dopaminergic pathways [8] |
| Personality changes | Frontal lobe dysfunction → disinhibition, apathy, irritability [8] |
| Neurosis | Generalised cortical dysfunction [8] |
| Psychosis | Dopaminergic pathway disruption in mesolimbic system [8] |
| Cognitive decline | Diffuse cortical copper deposition |
| Behavioural problems (in children) | Early cortical involvement; often misattributed to adolescent issues |
A critical pitfall: patients may first present to psychiatry and be misdiagnosed with a primary psychiatric disorder for years before the true diagnosis is made.
| Symptom | Pathophysiological Basis |
|---|---|
| Haematuria | Renal copper deposition → tubular damage [3] |
| Polyuria, polydipsia | Fanconi syndrome → osmotic diuresis from glycosuria and impaired concentrating ability |
| Bone pain/fractures | Osteoporosis from Fanconi syndrome (phosphaturia → hypophosphataemia → impaired mineralisation); also from chronic liver disease |
| Joint pain/swelling | Copper deposition in cartilage → premature osteoarthritis, CPPD crystal deposition (Wilson's disease is an associated metabolic cause of CPPD disease) [10] |
| Menstrual irregularity/amenorrhoea | Chronic liver disease → impaired oestrogen metabolism; copper toxicity to reproductive organs |
Signs
| Sign | Pathophysiological Basis |
|---|---|
| Jaundice | As above — hepatocellular damage |
| Hepatomegaly (early) | Copper-laden, inflamed liver; may be replaced by a shrunken liver in advanced cirrhosis |
| Splenomegaly | Portal hypertension → congestion of splenic sinusoids |
| Ascites | Portal hypertension (↑ splanchnic hydrostatic pressure) + hypoalbuminaemia (↓ oncotic pressure) + RAAS activation (Na⁺/water retention) |
| Spider naevi | Hyperoestrogenism from impaired hepatic oestrogen metabolism → arteriolar vasodilation |
| Palmar erythema | Same mechanism as spider naevi |
| Caput medusae | Portal hypertension → porto-systemic anastomosis at umbilical vein |
| Flapping tremor (asterixis) | Hepatic encephalopathy → metabolic disturbance of reticular activating system |
| Gynaecomastia | Hyperoestrogenism in males |
| Dupuytren's contracture | Hepatic fibrosis → (mechanism incompletely understood, associated with chronic liver disease) |
Ophthalmic: Kayser-Fleischer rings, sunflower cataracts [8]
| Sign | Pathophysiological Basis |
|---|---|
| Kayser-Fleischer (KF) rings | Copper deposits in Descemet's membrane of the cornea → golden-brown/greenish ring at the corneal periphery (limbus) [3]. Best detected by slit-lamp examination. Present in 99% of patients with neuropsychiatric symptoms and 30–50% with hepatic symptoms [3] |
| Sunflower cataracts | Copper deposits in the lens → distinctive petal-like, sunflower appearance [3]. Less common than KF rings. Does not usually impair vision significantly |
KF Rings – Must Know
KF rings are NOT pathognomonic for Wilson's disease (they can rarely occur in other cholestatic liver diseases such as PBC). However, in a young patient with liver disease or neurological symptoms, KF rings are virtually diagnostic. The absence of KF rings does NOT exclude Wilson's disease — they are absent in up to 50–70% of patients with purely hepatic presentations [3].
| Sign | Pathophysiological Basis |
|---|---|
| Resting tremor | Basal ganglia copper deposition → dopaminergic circuit disruption (Parkinsonian) |
| Wing-beating tremor | Cerebellar copper deposition → coarse, proximal, postural tremor |
| Rigidity (cogwheel or lead-pipe) | Basal ganglia damage → loss of normal inhibition of muscle tone |
| Bradykinesia | Striatal dopaminergic pathway disruption |
| Dystonia | Copper deposition in putamen → abnormal sustained postures |
| Chorea | Caudate nucleus damage → involuntary irregular movements |
| Cerebellar signs | Ataxia, dysmetria, dysdiadochokinesia, intention tremor, nystagmus — from cerebellar copper deposition |
| Pseudobulbar palsy | Bilateral UMN lesions → brisk jaw jerk, spastic dysarthria, dysphagia, emotional lability [8] |
| Risus sardonicus ("sardonic grin") | Dystonia of facial muscles — characteristic facies in advanced Wilson's disease |
| Sign | Pathophysiological Basis |
|---|---|
| Fanconi's syndrome | Proximal tubule transport defect due to copper deposition [3]: aminoaciduria, glycosuria, phosphaturia (→ hypophosphataemia, rickets/osteomalacia), uricosuria (→ low uric acid), bicarbonate wasting (→ Type 2/proximal RTA → metabolic acidosis) |
| Renal tubular acidosis | Bicarbonate wasting from proximal tubule damage |
| Nephrolithiasis | Hypercalciuria, hyperuricosuria from tubular dysfunction |
| Sign | Pathophysiological Basis |
|---|---|
| Coombs-negative haemolytic anaemia | Cu deposit in RBC membranes → oxidative damage → intravascular haemolysis. Coombs-negative because it is NOT antibody-mediated [3][7] |
| Thrombocytopenia | Hypersplenism from portal hypertension |
| Leucopoenia | Hypersplenism |
Fulminant Wilson's – Classic Exam Scenario
Fulminant hepatic failure due to Wilson's has a very specific feature: young patients with no reason for fulminant liver failure, exclusion of all other common causes → only finding is low haemoglobin → Coombs-negative haemolytic anaemia [7]. The combination of acute liver failure + Coombs-negative haemolytic anaemia + low ALP (paradoxically, because ALP is a zinc-dependent enzyme and zinc is competitively displaced by excess copper) is highly suggestive of Wilson's disease. AST/ALT ratio > 2 is also a clue [3].
| Sign | Pathophysiological Basis |
|---|---|
| Premature osteoarthritis | Copper deposition in articular cartilage → chondrocyte damage |
| Chondrocalcinosis | CPPD crystal deposition (Wilson's is a recognised metabolic disease associated with CPPD) [10] |
| Osteoporosis | Vitamin D deficiency (from Fanconi syndrome phosphaturia), chronic liver disease |
| Sign | Detail |
|---|---|
| Blue lunulae | Copper deposition in nail beds → bluish discolouration of the half-moon at the nail base |
| Cardiomyopathy | Copper deposition in myocardium → dilated or hypertrophic cardiomyopathy (rare) |
| Pancreatitis | Copper deposition in pancreas (rare) |
| System | Key Features | Mechanism |
|---|---|---|
| Liver | Acute hepatitis, chronic hepatitis, cirrhosis, fulminant liver failure | Direct copper toxicity → hepatocyte damage |
| CNS | Dysarthria, tremor (wing-beating), dystonia, Parkinsonism, chorea, ataxia, pseudobulbar palsy, seizures | Copper deposition in basal ganglia, cerebellum, brainstem |
| Psychiatric | Depression, personality changes, psychosis, neurosis | Copper deposition in cortex/limbic system |
| Eyes | KF rings, sunflower cataracts | Copper in Descemet's membrane and lens |
| Kidneys | Fanconi syndrome, haematuria, RTA | Copper toxicity to proximal tubules |
| Blood | Coombs-negative haemolytic anaemia | Copper in RBC membranes → oxidative haemolysis |
| MSK | Osteoarthritis, chondrocalcinosis, osteoporosis | Copper in cartilage + Fanconi phosphaturia |
| Cardiac | Cardiomyopathy, arrhythmias | Copper deposition in myocardium |
High Yield Summary
- Wilson's disease = AR mutation in ATP7B gene on chromosome 13 → defective copper-transporting P-type ATPase
- Two key functional losses: failure to incorporate copper into ceruloplasmin + failure to excrete copper into bile
- Copper accumulates in liver first (from birth) → hepatocyte damage → copper spills into blood → deposits in brain, cornea, kidneys, RBCs
- Children present with hepatic disease; older patients with neurological/psychiatric disease
- KF rings (Descemet's membrane) present in 99% with neuropsychiatric and 30–50% with hepatic disease
- Coombs-negative haemolytic anaemia is the hallmark haematological manifestation — non-immune, direct copper toxicity to RBCs
- Fulminant liver failure + Coombs-negative haemolytic anaemia + low ALP in a young patient = think Wilson's
- Most patients are compound heterozygotes; > 200 mutations identified
- Universally fatal if untreated
- Genetic test does not have to be positive to diagnose — clinical + biochemical diagnosis is sufficient given the genetic heterogeneity
- Wilson's disease is a recognised metabolic cause of CPPD crystal deposition disease
- Can mimic Parkinson's disease — always check copper studies in young-onset parkinsonism
Active Recall - Wilson's Disease (Part 1: Definition to Clinical Features)
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (Section 7.2.2 – Wilson Disease) [2] Senior notes: Ryan Ho GI.pdf (Section 4.5.3 – Wilson's Disease) [3] Senior notes: Maksim Medicine Notes.pdf (Wilson's disease) [4] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Wilson's disease) [5] Lecture slides: GC 025. A jaundiced and incoherent patient liver failure.pdf [6] Senior notes: Block A - A jaundiced and incoherent patient_ liver failure.pdf [7] Senior notes: Block A - Patients with non-viral chronic liver diseases.pdf [8] Lecture slides: Teaching Clinic - Non-viral chronic liver diseases (Prof. Yuen Man Fung) 2.pdf (Wilson's Disease slide) [9] Senior notes: Ryan Ho Neurology.pdf (Section on secondary parkinsonism) [10] Senior notes: Ryan Ho Rheumatology.pdf (CPPD crystal deposition disease)
Differential Diagnosis of Wilson's Disease
Wilson's disease is a diagnostic chameleon. Its protean manifestations span hepatology, neurology, psychiatry, haematology, nephrology and ophthalmology. Because it is rare (1 in 30,000) yet treatable and universally fatal if untreated [1], the clinician's task is twofold:
- When you suspect Wilson's — confirm it efficiently.
- When a patient presents with one of Wilson's phenotypes (unexplained liver disease, young-onset movement disorder, psychiatric change, Coombs-negative haemolysis) — keep Wilson's in the differential and not miss it.
The differential diagnosis is therefore best organised by presenting phenotype, because that is how you will encounter these patients in clinical practice and in exams.
This is the most common initial presentation of Wilson's disease, particularly in children and adolescents. The liver disease can range from asymptomatic transaminase elevation to acute hepatitis, chronic hepatitis, cirrhosis, or fulminant liver failure.
GC High Yield – Metabolic Causes of Chronic Liver Disease
Wilson's disease is classified as a metabolic cause of chronic liver disease alongside haemochromatosis and α1-antitrypsin deficiency [5][7]. In the GC lecture on non-viral chronic liver diseases, these three metabolic conditions are specifically highlighted as important differentials when common viral and alcoholic aetiologies have been excluded [8].
| Differential | Key Distinguishing Features | Why it mimics Wilson's |
|---|---|---|
| Viral hepatitis (HBV, HCV, HAV, HEV) | Viral serology positive; HAV/HEV usually self-limiting; HBV/HCV can cause chronic disease. HBV extremely common in HK [11][12] | Acute hepatitis from Wilson's is clinically indistinguishable from acute viral hepatitis [1] — jaundice, abdominal pain, raised transaminases (though usually lower than viral) |
| Autoimmune hepatitis (AIH) | Autoantibodies (ANA, ASMA, anti-LKM1); elevated IgG; responds to immunosuppression; female predominance. Histological features of Wilson's are similar to autoimmune hepatitis and NASH including fatty infiltration, glycogen inclusions, portal fibrosis [4] | Can present at similar age; chronically elevated transaminases; autoantibodies are not specific and AIH sometimes becomes a diagnosis of exclusion [11] |
| NAFLD / NASH | Obesity, metabolic syndrome, insulin resistance; USS shows fatty liver; no KF rings, normal copper studies | Both can cause fatty liver on histology; Wilson's can cause hepatic steatosis in early stages |
| Drug-induced liver injury (DILI) | Temporal relationship with drug exposure; pattern (hepatocellular vs cholestatic vs mixed) depends on causative drug | Both present with elevated transaminases; important to take a thorough drug history |
| Alcoholic liver disease | Significant alcohol intake history; AST > ALT (usually AST:ALT ≈ 2:1) but AST rarely exceeds 500 [11]; GGT disproportionately elevated | Wilson's also has AST > ALT (ratio > 2) [3] — but occurs in a young patient without alcohol history, which is the key differentiator |
| α1-antitrypsin (A1AT) deficiency | Low serum α1-antitrypsin level; PiZZ phenotype; associated emphysema (panlobular, lower lobes); PAS-positive, diastase-resistant globules on liver biopsy | Both are AR metabolic causes of chronic liver disease in young patients |
| Hereditary haemochromatosis (HH) | Elevated ferritin and transferrin saturation; HFE gene mutation (C282Y, H63D); iron deposition on MRI; bronze diabetes, arthropathy | Both are inherited metabolic diseases causing chronic liver disease; both are risk factors for HCC [13]; haemochromatosis more common in Caucasians, much rarer in Hong Kong Chinese |
| Primary biliary cholangitis (PBC) | Middle-aged women; pruritus; M2 isoform of anti-mitochondrial antibody (AMA) is highly specific [7]; cholestatic LFT pattern (elevated ALP/GGT >> AST/ALT) | Rarely confused clinically, but both can cause KF rings (very rare in PBC — copper retention from chronic cholestasis can deposit in cornea) |
| Primary sclerosing cholangitis (PSC) | Male predominance; associated with IBD (especially UC); "beading" of bile ducts on MRCP; cholestatic pattern | Rarely mimics Wilson's but both can cause chronic liver disease |
Critical Exam Point
HBV and HCV serology must be performed to rule out other differential diagnoses including chronic viral hepatitis [4]. In Hong Kong, HBV is the leading cause of chronic liver disease and HCC — it is essential to exclude this first. However, a positive HBsAg does NOT exclude coexisting Wilson's disease. Even if HBsAg is positive, it may not explain the current liver presentation [11] — always consider whether the clinical picture truly fits viral hepatitis alone.
How to Distinguish Wilson's from These Hepatic Mimics
The key discriminating investigations are:
- Age: Wilson's presents in young patients (5–35 years); viral hepatitis can occur at any age
- Low ceruloplasmin ( < 20 mg/dL): absent in other causes (though can be low in severe liver failure of any cause, malnutrition, nephrotic syndrome)
- Elevated 24-hour urinary copper ( > 100 μg): relatively specific
- KF rings on slit-lamp examination: present in ~30–50% with hepatic disease [3]
- No single test is diagnostic [8] — diagnosis requires a combination of findings (Leipzig score)
Wilson's disease typically causes extrapyramidal symptoms (parkinsonism, dystonia, chorea) and/or cerebellar signs (ataxia, tremor, dysarthria). The differential here is essentially the differential for movement disorders in a young person.
Wilson's disease must be considered in the differential of secondary (symptomatic) parkinsonism [9]. Drug-induced parkinsonism from metoclopramide, antipsychotics, or antihistamines is particularly important to identify as it is reversible [14].
| Differential | Key Distinguishing Features | Why it mimics Wilson's |
|---|---|---|
| Idiopathic Parkinson's disease (IPD) | Onset 40–70 years (peak 6th decade); unilateral onset; resting pill-rolling tremor; responds well to levodopa; Lewy body pathology [9] | Wilson's can mimic Parkinson's disease — extrapyramidal deposition of copper [7]. BUT Wilson's presents earlier (5–35y), often bilateral, and tremor is more often postural/kinetic (wing-beating) rather than pure resting |
| Drug-induced parkinsonism | Temporal relationship with offending drug (neuroleptics, metoclopramide, antiemetics, lithium); usually bilateral and symmetrical; resolves on drug withdrawal [9] | Both cause extrapyramidal signs in young people; drug history is the key |
| Huntington's disease | AD inheritance; CAG trinucleotide repeat on chromosome 4p16.3; chorea + psychiatric manifestations + progressive dementia [14]; caudate atrophy on MRI | Both can cause chorea and psychiatric symptoms in young patients; but Huntington's is AD (vs Wilson's AR), and typically presents later (30–50y) with chorea > parkinsonism |
| Progressive supranuclear palsy (PSP) | Older patients (> 60y); vertical gaze palsy (initially downgaze); axial rigidity > limb rigidity; frequent falls; poor levodopa response [9] | Both cause parkinsonism but PSP is an older-onset disease |
| Multiple system atrophy (MSA) | Older onset; prominent autonomic dysfunction (postural hypotension, urinary incontinence); cerebellar signs (MSA-C) or parkinsonism (MSA-P); poor levodopa response [9] | Both can cause cerebellar signs + parkinsonism, but MSA is older-onset |
| Neurodegeneration with brain iron accumulation (NBIA, Hallervorden-Spatz syndrome) | Childhood/adolescent onset; dystonia, parkinsonism; "eye-of-the-tiger" sign on MRI (iron deposition in globus pallidus) [9] | Both cause young-onset dystonia/parkinsonism; but NBIA has characteristic MRI and no copper abnormality |
| Toxic exposure (MPTP, manganese, CO poisoning) | Relevant exposure history; bilateral symmetrical parkinsonism [9] | Young onset parkinsonism — exposure history is key |
| Cerebral arteriosclerotic disease (vascular parkinsonism) | Stepwise deterioration; LL > UL involvement; more symmetrical; poor levodopa response; vascular risk factors [9] | Rarely confused but both can cause gait problems; vascular parkinsonism is in older patients |
| Normal pressure hydrocephalus (NPH) | Classical triad: frontal dementia, apraxic gait, urinary incontinence [15]; all ventricles enlarged on imaging | Gait abnormality can overlap, but NPH has characteristic triad and imaging |
Wilson's disease can present with depression, neurosis, personality changes, psychosis [8]. These may precede neurological or hepatic features by months to years.
| Differential | Key Distinguishing Features |
|---|---|
| Primary depressive disorder | No neurological signs; no liver disease; normal copper studies; responds to antidepressants |
| Schizophrenia / psychotic disorder | Typically presents in late teens/early 20s; no liver or neurological signs; family history of psychotic illness |
| Bipolar disorder | Episodic mood changes; no progressive neurological decline |
| Substance abuse | Relevant substance history; toxicology screen |
| Organic causes | Thyroid disease (TFT), SLE (ANA, anti-dsDNA), neurosyphilis (VDRL), Wilson's disease (copper studies), HIV |
The key teaching point: always investigate for organic causes in any young patient with new-onset psychiatric symptoms, especially if accompanied by subtle neurological signs (tremor, dysarthria, gait change) or unexplained liver enzyme elevation. Copper studies for Wilson's disease should be part of the organic workup [16].
Coombs-negative haemolytic anaemia is a hallmark of Wilson's disease [3][7]. The differential of haemolytic anaemia is divided by the Coombs test result:
| Category | Coombs Test | Examples | How Wilson's differs |
|---|---|---|---|
| Immune haemolysis | Positive | Warm AIHA, cold AIHA, drug-induced immune haemolysis, alloimmune (transfusion reaction, HDN) | Wilson's is Coombs negative — haemolysis is from direct copper toxicity, not antibodies [3][17] |
| Non-immune: Membrane defects | Negative | Hereditary spherocytosis, hereditary elliptocytosis | Family history; abnormal osmotic fragility; no liver disease |
| Non-immune: Enzyme defects | Negative | G6PD deficiency (common in HK and Southern Chinese) | Episodic, triggered by drugs/fava beans/infection; G6PD assay; no liver disease |
| Non-immune: Haemoglobinopathy | Negative | Sickle cell disease, thalassaemia | Hb electrophoresis; ethnic predisposition; no copper abnormality |
| Non-immune: Fragmentation | Negative | TTP, HUS, DIC, mechanical heart valves, HELLP | Schistocytes on blood film; thrombocytopenia; renal impairment (in TTP/HUS) |
| Non-immune: Infection | Negative | Malaria, Clostridium, Babesia | Travel history; blood film for parasites |
| Non-immune: PNH | Negative | Paroxysmal nocturnal haemoglobinuria | Flow cytometry (loss of CD55/CD59); pancytopenia; thrombosis |
| Non-immune: Toxin | Negative | Wilson's disease [3], copper sulfate poisoning, arsenic, lead | Wilson's: young patient + liver disease + low ceruloplasmin + elevated urine copper |
Classic Exam Scenario – Fulminant Wilson's
Fulminant hepatic failure due to Wilson's has a very specific feature: young patients with no reason for fulminant liver failure, exclusion of all other common causes → only finding is low haemoglobin → Coombs-negative haemolytic anaemia [7]. The triad of ALF + Coombs-negative haemolysis + paradoxically low ALP in a young patient should scream Wilson's disease.
This is perhaps the most critical differential because it is life-threatening and Wilson's disease causing ALF has a specific management pathway (liver transplantation).
| Differential | Key Distinguishing Features |
|---|---|
| Viral hepatitis (HAV, HBV, HEV) | Viral serology; exposure history; HBV common in HK [11][12] |
| Paracetamol overdose | Drug history; paracetamol level; characteristically sky-high transaminases (> 3000) with rapid fall |
| Autoimmune hepatitis | Autoantibodies; elevated IgG; may present fulminantly; can coexist with Wilson's [11] |
| Drug/toxin-induced | Exposure history; specific drug patterns |
| Wilson's disease | Young patient; Coombs-negative haemolytic anaemia; low ALP; AST:ALT > 2; low ceruloplasmin [3][4][7] |
| Pregnancy-related (AFLP, HELLP) | 3rd trimester; thrombocytopenia (HELLP); microvesicular steatosis (AFLP) |
| Ischaemic hepatitis | Haemodynamic instability/shock preceding liver injury; massive LDH elevation [11]; rapid rise and fall of transaminases |
| Budd-Chiari syndrome | Hepatic vein thrombosis; prothrombotic states; ascites disproportionate to liver disease |
A useful discriminating feature for Wilson's ALF: the AST:ALT ratio is usually > 2 [3] and ALP is paradoxically low (zinc-dependent enzyme; excess copper displaces zinc → reduced ALP activity). The ALP:total bilirubin ratio < 4 and AST:ALT ratio > 2.2 have been proposed as highly sensitive and specific for Wilson's disease as a cause of ALF.
6. Miscellaneous DDx by System
- Other causes of acquired Fanconi syndrome: multiple myeloma (light chains), aminoglycosides, tenofovir, expired tetracyclines, heavy metals (lead, cadmium)
- Differentiate by: copper studies, drug history, serum/urine protein electrophoresis
- Wilson's disease is a recognised metabolic cause of CPPD crystal deposition disease, alongside haemochromatosis, hyperparathyroidism, hypomagnesaemia and hypophosphatasia [10]
- In a young patient with chondrocalcinosis, always consider these secondary causes — CPPD in someone < 55 years old should trigger a metabolic screen
- KF rings are NOT 100% specific for Wilson's — they can very rarely occur in primary biliary cholangitis (chronic cholestasis → copper retention → corneal deposition) and other cholestatic diseases
- However, in the right clinical context (young patient, liver/neurological disease), KF rings are virtually pathognomonic
| Feature | Wilson's | Viral hepatitis | AIH | NAFLD | Haemochromatosis | A1AT deficiency | IPD |
|---|---|---|---|---|---|---|---|
| Age | 5–35y | Any | Young–middle-aged | Middle-aged | 40–60y (M) | Young (liver); 30–50 (lung) | 40–70y |
| Inheritance | AR | N/A | Polygenic | N/A | AR (HFE) | AR (SERPINA1) | Mostly sporadic |
| Ceruloplasmin | ↓ | Normal | Normal | Normal | Normal | Normal | Normal |
| Urine copper | ↑ | Normal | Normal | Normal | Normal | Normal | Normal |
| KF rings | + (30–99%) | − | − | − | − | − | − |
| Haemolysis | Coombs − | Rare | Rare | No | No | No | No |
| LFT pattern | AST > ALT | ALT > AST (viral) | ALT > AST | ALT > AST | Mild elevation | Variable | Normal |
| Key test | Copper studies, Leipzig score | Viral serology | Autoantibodies, IgG | USS, metabolic screen | Ferritin, transferrin sat, HFE | α1-AT level, Pi typing | Clinical criteria, DaTscan |
No single test is diagnostic [8] — diagnosis requires integration of clinical, biochemical, and sometimes histological and genetic data.
Diagnosis of Wilson's disease: No single test for diagnosis — serum copper, serum ceruloplasmin, 24-hour urinary copper excretion, liver biopsy with quantitative copper concentrations, slit-lamp examination for KF rings [8]. Family screening of first-degree relatives must be undertaken [8].
The approach is:
- Suspect Wilson's in any patient < 40 years with unexplained liver disease, neuropsychiatric symptoms, or Coombs-negative haemolytic anaemia
- Screen with serum ceruloplasmin, 24h urinary copper, slit-lamp exam for KF rings
- Confirm with Leipzig scoring system ± liver biopsy (hepatic copper concentration ≥ 250 μg/g dry weight is diagnostic [4]) ± ATP7B mutation analysis
- Exclude common mimics: viral serology, autoimmune screen, metabolic screen, drug history
High Yield Summary – Differential Diagnosis
- Hepatic DDx: Viral hepatitis (especially HBV in HK), AIH, NAFLD, DILI, haemochromatosis, A1AT deficiency — all can cause chronic liver disease in young patients. Wilson's is distinguished by low ceruloplasmin, elevated urine copper, KF rings.
- Neurological DDx: IPD, drug-induced parkinsonism, Huntington's, NBIA — Wilson's presents younger and has systemic features (liver disease, KF rings). Always check copper studies in young-onset movement disorders.
- Haematological DDx: All causes of Coombs-negative haemolytic anaemia — Wilson's is distinguished by coexisting liver disease and copper metabolic derangement.
- ALF DDx: Viral, paracetamol, AIH — Wilson's ALF has the classic triad: Coombs-negative haemolysis + low ALP + AST:ALT > 2.
- Psychiatric DDx: Always investigate organic causes in young patients with new psychiatric symptoms — Wilson's is treatable.
- No single test is diagnostic — use the Leipzig scoring system incorporating multiple parameters.
- Family screening of first-degree relatives must be undertaken once a proband is identified.
Active Recall - Wilson's Disease Differential Diagnosis
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (Section 7.2.2 – Wilson Disease) [3] Senior notes: Maksim Medicine Notes.pdf (Wilson's disease) [4] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Wilson's disease – Diagnosis) [5] Lecture slides: GC 025. A jaundiced and incoherent patient liver failure.pdf [7] Senior notes: Block A - Patients with non-viral chronic liver diseases.pdf [8] Lecture slides: Teaching Clinic - Non-viral chronic liver diseases (Prof. Yuen Man Fung) 2.pdf (Wilson's Disease – Diagnosis slide) [9] Senior notes: Ryan Ho Neurology.pdf (Section 5.2 – Parkinsonism DDx) [10] Senior notes: Ryan Ho Rheumatology.pdf (CPPD crystal deposition disease) [11] Senior notes: Block A - Gastrointestinal Data Interpretation.pdf [12] Senior notes: Block A - Jaundice after raw oysters_ acute hepatitis.pdf [13] Senior notes: Maksim Surgery Notes.pdf (Hepatocellular carcinoma) [14] Senior notes: learning_points_output.txt (Neurology – Two Cases of Movement Disorders) [15] Senior notes: Ryan Ho Psychiatry.pdf (Dementia – NPH) [16] Senior notes: Ryan Ho Neurology.pdf (Dementia workup – copper studies) [17] Senior notes: Block A - Family history of anaemia_ inherited causes of anaemia; haemolytic anaemia; aplastic anaemia.pdf
Diagnostic Criteria, Algorithm and Investigations for Wilson's Disease
Before diving into the specifics, understand why Wilson's disease is notoriously hard to diagnose:
- It is rare (1 in 30,000) — most clinicians will see very few cases in their career
- It is protean — presentations span hepatology, neurology, psychiatry, haematology, nephrology
- No single test is diagnostic [8] — each individual test has limitations (false positives and false negatives)
- Ceruloplasmin can be normal in up to 10% of Wilson's patients [3]
- KF rings can be absent in up to 50–70% of patients with purely hepatic disease [3]
- Genetic testing does not have to be positive to reach a diagnosis because the hereditary pathway of Wilson's is very heterogeneous — not just ATP7B [7]
Therefore, diagnosis relies on a composite scoring system (Leipzig score) that integrates multiple parameters.
Suspect Wilson's disease if abnormal LFT with clinical presentations (e.g. dystonia, psychiatric symptoms) at young age ( < 30) [3]
Specific triggers to investigate:
- Unexplained liver disease in a patient aged 5–40 years (any pattern: acute hepatitis, chronic hepatitis, cirrhosis, fulminant liver failure)
- Young-onset movement disorder (parkinsonism, dystonia, tremor, chorea, ataxia, dysarthria)
- New psychiatric symptoms in a young person with concurrent subtle neurological signs or liver enzyme elevation
- Coombs-negative haemolytic anaemia, especially if accompanied by liver disease
- Acute liver failure in a young patient with haemolysis and paradoxically low ALP
- Unexplained Fanconi syndrome in a young person
- Chondrocalcinosis or CPPD disease in a patient < 55 years (metabolic screen indicated)
- Sibling of a known Wilson's disease patient (family screening)
Investigation Modalities — Detailed Breakdown
A. First-Line Screening Investigations
| Parameter | Detail |
|---|---|
| What it is | Ceruloplasmin is an α2-glycoprotein synthesised in the liver that carries ~90% of circulating copper. It also has ferroxidase activity (oxidises Fe²⁺ → Fe³⁺ for loading onto transferrin) |
| Why it is low in Wilson's | ATP7B normally incorporates copper into apoceruloplasmin → holoceruloplasmin. Without copper incorporation, apoceruloplasmin (copper-free form) has a much shorter half-life → it is degraded rapidly → ↓ serum ceruloplasmin [1][2][3] |
| Diagnostic threshold | < 20 mg/dL (or < 0.2 g/L) is considered low [3][4] |
| Sensitivity | ~85–90% — normal in up to 10% of patients [3] |
| False negatives (normal ceruloplasmin in Wilson's) | Ceruloplasmin is an acute-phase reactant → levels can be "falsely" normal/elevated in inflammation, infection, pregnancy, oestrogen use, malignancy |
| False positives (low ceruloplasmin without Wilson's) | Severe liver failure of any cause (reduced synthetic capacity), nephrotic syndrome (urinary protein loss), protein-losing enteropathy, malnutrition, aceruloplasminaemia (rare AR disorder of iron metabolism), heterozygous ATP7B carriers (~20% have mildly low levels), Menkes disease (X-linked copper deficiency) |
Exam Pitfall – Ceruloplasmin
A normal ceruloplasmin does NOT exclude Wilson's disease. Conversely, a low ceruloplasmin does not confirm it. This is precisely why no single test is diagnostic [8] and why the Leipzig scoring system exists.
| Parameter | Detail |
|---|---|
| Why it is elevated | Damaged hepatocytes release stored copper → increased free (non-ceruloplasmin-bound) copper in the blood → filtered by glomeruli → ↑ 24h urine Cu [2][3] |
| Diagnostic threshold | > 100 μg/day (> 1.6 μmol/day) in symptomatic patients is diagnostic when combined with other features [3][4] |
| In children | Threshold may be lower; > 40 μg/day is considered suspicious [4] |
| Penicillamine challenge test | If baseline urinary copper is equivocal, administer 500 mg D-penicillamine at start and again 12 hours later during the 24h collection. In Wilson's disease, urinary copper typically increases to > 1600 μg/day (> 25 μmol/day). This test is useful in paediatric patients with borderline results |
| False positives | Cholestatic liver disease (impaired biliary copper excretion → overflow into urine), autoimmune hepatitis, contamination of collection |
| False negatives | Very early disease (before significant hepatocyte damage), incomplete collection |
| Parameter | Detail |
|---|---|
| What they are | Copper deposits in Descemet's membrane of the cornea, appearing as golden-brown/greenish rings at the limbus [3] |
| Detection method | Slit-lamp examination — KF rings may NOT be visible to the naked eye, especially in dark-eyed individuals. Slit-lamp by an experienced ophthalmologist is mandatory [4][8] |
| Sensitivity | Present in 99% of patients with neuropsychiatric symptoms and 30–50% of patients with hepatic symptoms [3] |
| Specificity | High but NOT 100% — can rarely be seen in chronic cholestatic diseases (PBC, PSC) where prolonged copper retention occurs |
| Sunflower cataracts | Copper deposits in the lens — less common than KF rings; petal-like opacities on slit-lamp [4] |
Slit-lamp examination for KF rings is one of the key diagnostic investigations listed by Prof. Yuen [8].
| Parameter | Detail |
|---|---|
| Total serum copper | Paradoxically LOW in most Wilson's patients — because ~90% of serum copper is bound to ceruloplasmin, and ceruloplasmin is low. So total copper = ceruloplasmin-bound (low) + free copper (high), but the drop in ceruloplasmin-bound copper predominates |
| Free (non-ceruloplasmin-bound) copper | HIGH — this is the toxic fraction. Calculated as: Free Cu = Total Cu (μg/dL) − [3.15 × ceruloplasmin (mg/dL)]. Normal free copper is 10–15 μg/dL; in Wilson's disease it is typically > 25 μg/dL |
| Why this matters | Total serum copper can be misleadingly low; the clinically relevant measurement is free copper, which reflects the copper causing tissue damage |
B. Second-Line / Confirmatory Investigations
Liver biopsy is the GOLD standard for diagnosis [4]
| Parameter | Detail |
|---|---|
| Why it is the gold standard | Directly measures copper content in the liver — the primary site of accumulation |
| Diagnostic threshold | Hepatic copper concentration ≥ 250 μg/g of dry weight is diagnostic [4] |
| Exclusion threshold | Hepatic copper concentration < 50 μg/g of dry weight effectively excludes Wilson's [4] |
| Grey zone | 50–250 μg/g: molecular genetic testing is indicated if histology reveals evidence of active liver disease [4] |
| Histological features | Similar to autoimmune hepatitis and non-alcoholic steatohepatitis including fatty infiltration within hepatocytes, glycogen inclusions within nuclei, and portal fibrosis [4]. Special stains: rhodanine or rubeanic acid stain for copper; orcein stain for copper-associated protein. Note: these stains have low sensitivity — quantitative measurement is essential |
| Limitations | Sampling variation may lead to false-negative results and hepatic copper concentration should always be evaluated in the context of other diagnostic criteria [4]; contraindicated in severe coagulopathy (e.g., fulminant liver failure — precisely when you need it most) |
Key Concept – Why Biopsy Histology Can Be Misleading
Histological features are similar to autoimmune hepatitis and NASH [4]. Without quantitative copper measurement, the biopsy alone may lead to a misdiagnosis of AIH or NASH. Always request quantitative hepatic copper concentration alongside histology.
| Parameter | Detail |
|---|---|
| When indicated | When the diagnosis remains unclear despite liver biopsy, or to aid screening of family members when the mutation in the proband is known [4] |
| NOT for initial diagnosis | Abundance of disease-specific mutations complicates genetic testing. The genetic component of the disease is heterogeneous such that there are presence of other mutation types causing Wilson's disease that are not currently known [4][7] |
| For family screening | Family screening of siblings should begin with mutation analysis for ATP7B mutation if the identified patient (proband) has been tested [4] |
| Practical point | In East Asian / Chinese populations, R778L is the most common mutation (vs H1069Q in Europeans). Targeted panels may miss rare/novel mutations → full gene sequencing may be needed |
Genetic test does not have to be positive to reach a diagnosis → with compatible clinical and history, you can still diagnose [7]. This is a critical exam point: a negative genetic test does NOT exclude Wilson's disease.
C. Supportive / Ancillary Investigations
| Finding | Interpretation |
|---|---|
| Coombs-negative haemolytic anaemia | Associated with acute liver failure in Wilson's disease but can occur episodically independent of liver failure. Results from effects of excess copper ions on the RBC membrane in the circulation due to hepatic copper release following cellular necrosis [4] |
| Reticulocytosis | Bone marrow compensatory response to haemolysis |
| Thrombocytopenia | Hypersplenism due to portal hypertension in patients with liver cirrhosis [4] |
| Leucopenia | Hypersplenism |
| Blood film | May show spherocytes (non-specific); schistocytes are NOT expected (this is not microangiopathic) |
| Finding | Interpretation |
|---|---|
| Negative | Confirms haemolysis is NOT immune-mediated — this is direct copper toxicity to RBC membranes |
| Finding | Interpretation |
|---|---|
| ↑ AST and ALT (aminotransferases) | Reflect hepatocellular damage from copper accumulation [4] |
| AST is usually higher than ALT (ratio > 2) in patients with Wilson's disease | This is unusual — most hepatocellular diseases (e.g., viral hepatitis) have ALT > AST. The 4 cases where AST > ALT include: Alcoholic hepatitis, Cirrhosis (any cause), Wilson's disease, and ischaemic/cardiac hepatitis [11]. The reason AST > ALT in Wilson's relates to the degree of mitochondrial damage (AST has a mitochondrial isoform released in more severe injury) and possibly to associated cirrhosis |
| Low ALP | Paradoxically low in fulminant Wilson's — ALP is a zinc-dependent metalloenzyme; excess copper displaces zinc, reducing enzyme activity. ALP:bilirubin ratio < 4 is a useful diagnostic clue in ALF |
| ↑ Bilirubin | Combination of hepatocellular damage + haemolysis (unconjugated fraction from haemolysis, conjugated from liver dysfunction) |
| Low albumin | Impaired hepatic synthetic function (if chronic disease/cirrhosis) |
| Finding | Interpretation |
|---|---|
| Coagulopathy | Secondary to cirrhosis or acute liver failure [4] — impaired hepatic synthesis of clotting factors (II, VII, IX, X) |
| Elevated INR | Important for prognostication and transplant listing (King's College criteria, New Wilson Index) |
| Finding | Interpretation |
|---|---|
| Rule out other differential diagnosis including chronic viral hepatitis [4] | HBsAg, anti-HCV IgG, and if positive: HBV DNA, HBeAg, anti-HBc IgM (for HBV); HCV RNA (for HCV). Essential in HK where HBV is endemic |
| Investigation | Finding | Interpretation |
|---|---|---|
| LDH | Elevated | Reflects haemolysis (LDH released from lysed RBCs) |
| Haptoglobin | Low | Consumed by binding free haemoglobin released during haemolysis |
| Uric acid | Low | Fanconi syndrome → renal uric acid wasting |
| Phosphate | Low | Fanconi syndrome → phosphaturia |
| ABG | Normal anion gap metabolic acidosis | Fanconi syndrome → proximal RTA (type 2) — bicarbonate wasting |
| Urinalysis | Glycosuria, aminoaciduria, phosphaturia | Fanconi syndrome — generalised proximal tubule transport defect |
| Serum urea | May be low | Impaired hepatic urea cycle in liver failure |
D. Radiological Investigations
| Finding | Interpretation |
|---|---|
| MOST common finding is increased T2 signal intensity in the basal ganglia | Copper deposition → oedema, gliosis, neuronal loss in putamen, caudate, thalamus [4] |
| "Face of giant panda sign" | Hyperintense signal in the tegmentum of midbrain especially around red nucleus which has normal hypointensity [4] — the normal dark red nucleus surrounded by bright signal creates the "eyes" of the panda face. This is a classic but NOT always present sign |
| T1 hyperintensity | May be seen in globus pallidus due to copper/manganese deposition or chronic hepatic encephalopathy |
| Cortical and cerebellar atrophy | In advanced disease |
MRI brain: "face of giant panda" in midbrain [3]
| Investigation | Finding |
|---|---|
| MRI liver | Can show iron and copper co-deposition; elastography for fibrosis staging |
| FibroScan (transient elastography) | Non-invasive fibrosis assessment — useful for monitoring rather than initial diagnosis |
| X-ray joints | Chondrocalcinosis, premature degenerative changes |
Diagnostic Criteria
This practical algorithm from the senior notes [4] integrates the three core screening tests:
| Serum Ceruloplasmin | KF Ring | 24h Urine Copper | Result |
|---|---|---|---|
| Low ( < 20 mg/dL) | Present | > 40 μg | Diagnostic |
| Low ( < 20 mg/dL) | Present | ≤ 40 μg | Liver biopsy OR genetic testing required |
| Low ( < 20 mg/dL) | Absent | > 100 μg | Diagnostic |
| Low ( < 20 mg/dL) | Absent | ≤ 100 μg | Liver biopsy OR genetic testing required |
| Normal (≥ 20 mg/dL) | Present | Any | Liver biopsy OR genetic testing required |
| Normal (≥ 20 mg/dL) | Absent | > 40 μg | Liver biopsy OR genetic testing required |
| Normal (≥ 20 mg/dL) | Absent | ≤ 40 μg | Diagnosis EXCLUDED |
GC High Yield – Diagnostic Table
This diagnostic combination table is likely directly testable on HKUMed exams. The key principle: you need at least two abnormal tests to diagnose, or if only one is abnormal, proceed to liver biopsy or genetic testing. The only scenario where diagnosis is excluded is when ceruloplasmin is normal, KF rings are absent, AND urine copper is ≤ 40 μg.
The Leipzig score [3] is the internationally adopted semi-quantitative scoring system for Wilson's disease diagnosis. It was developed at the 8th International Meeting on Wilson's disease in Leipzig (2001) and remains the EASL/AASLD recommended tool.
| Parameter | Finding | Score |
|---|---|---|
| KF rings | Present | +2 |
| Absent | 0 | |
| Neuropsychiatric symptoms | Severe | +2 |
| Mild | +1 | |
| Absent | 0 | |
| Coombs-negative haemolytic anaemia | Present | +1 |
| Absent | 0 | |
| 24h urinary copper | > 2× ULN (> 100 μg) | +2 |
| 1–2× ULN (40–100 μg) | +1 | |
| Normal ( < 40 μg) | 0 | |
| Liver copper (quantitative) | > 250 μg/g (> 4 μmol/g) | +2 |
| 50–250 μg/g | +1 | |
| Normal ( < 50 μg/g) | −1 | |
| Rhodanine-positive hepatocytes | Present | +1 |
| Absent | 0 | |
| Serum ceruloplasmin | < 10 mg/dL | +2 |
| 10–20 mg/dL | +1 | |
| > 20 mg/dL | 0 | |
| Mutation analysis | Two disease-causing mutations detected | +4 |
| One disease-causing mutation detected | +1 | |
| No mutations detected | 0 |
Interpretation:
| Total Score | Interpretation |
|---|---|
| ≥ 4 | Diagnosis established |
| 3 | Possible — more tests needed |
| ≤ 2 | Diagnosis unlikely |
Leipzig Score – Exam Favourite
You do NOT need to memorise every point value, but you should know the principle: it is a composite score integrating clinical (KF rings, neuropsych, haemolysis), biochemical (ceruloplasmin, urine copper), histological (liver copper), and genetic (ATP7B mutation) parameters. A score ≥ 4 establishes the diagnosis. Finding two mutations on ATP7B alone gives +4 — immediately diagnostic.
When a young patient presents with acute liver failure and the question is "Is this Wilson's?", specific biochemical ratios are highly discriminating:
| Parameter | Cut-off | Sensitivity/Specificity |
|---|---|---|
| ALP : total bilirubin ratio | < 4 | Sensitivity 94%, Specificity 96% |
| AST : ALT ratio | > 2.2 | Sensitivity 94%, Specificity 86% |
If BOTH ratios are met → sensitivity 100%, specificity 100% for Wilson's as the cause of ALF (in the original derivation cohort). These are sometimes called the Berman criteria.
Additionally, the New Wilson Index (NWI) / Revised King's Score is used for prognostication and transplant listing in fulminant Wilson's — incorporates serum bilirubin, INR, AST, WCC, and albumin. A score ≥ 11 predicts death without liver transplant.
Family screening of first-degree relatives must be undertaken [8] once a diagnosis is established. This is explicitly stated in Prof. Yuen's lecture slide.
Once a proband (index case) is diagnosed:
- All first-degree relatives (especially siblings — 25% risk if both parents are carriers) should be screened
- Screening includes: serum ceruloplasmin, 24h urinary copper, LFT, slit-lamp examination
- Family screening of siblings should begin with mutation analysis for ATP7B mutation if the identified patient (proband) has been tested [4] — this is the most efficient approach when the proband's mutations are known
- Asymptomatic affected siblings should be treated (usually with zinc maintenance therapy) to prevent disease progression
| Investigation | Key Finding in Wilson's | Sensitivity | Limitations |
|---|---|---|---|
| Serum ceruloplasmin | < 20 mg/dL | ~85–90% | Normal in 10%; affected by inflammation, pregnancy, oestrogen |
| 24h urine copper | > 100 μg (symptomatic) | ~80–90% | Collection errors; equivocal in early disease |
| Slit-lamp | KF rings | 99% neuro; 30–50% hepatic | Not visible to naked eye; rare in other cholestatic disease |
| Liver biopsy | Hepatic Cu ≥ 250 μg/g dry wt | GOLD standard | Sampling error; contraindicated in coagulopathy |
| Free serum copper | > 25 μg/dL | Good | Calculated, depends on accurate ceruloplasmin |
| MRI brain | T2 hyperintensity basal ganglia; "face of giant panda" | High in neurological Wilson's | Not specific; absent in hepatic-only |
| ATP7B mutation analysis | 2 pathogenic mutations | High if found | > 200 mutations; many private; may miss novel variants |
| Leipzig score | ≥ 4 | Best composite accuracy | Requires multiple tests |
GC High Yield – Prof. Yuen's Lecture Points on Diagnosis
No single test for diagnosis. The key diagnostic investigations are:
- Serum copper
- Serum ceruloplasmin
- 24-hour urinary copper excretion
- Liver biopsy with quantitative copper concentrations
- Slit-lamp examination for KF rings
- Family screening of first-degree relatives must be undertaken [8]
These points are directly from the GC teaching clinic lecture and represent the expected exam answer framework.
High Yield Summary – Diagnosis
- No single test is diagnostic — use the Leipzig scoring system (≥ 4 = diagnosed)
- Three core screening tests: ceruloplasmin (< 20 mg/dL), 24h urine copper (> 100 μg), slit-lamp for KF rings
- Liver biopsy is the GOLD standard — hepatic Cu ≥ 250 μg/g dry weight is diagnostic, < 50 excludes
- Histology mimics AIH and NASH — always request quantitative copper alongside histology
- ATP7B genetic testing is NOT used for initial diagnosis due to genetic heterogeneity; reserved for unclear cases and family screening
- AST > ALT (ratio > 2) is a characteristic LFT pattern; low ALP is a clue in fulminant Wilson's
- Fulminant Wilson's ALF clues: Coombs-negative haemolysis + ALP:bilirubin < 4 + AST:ALT > 2.2
- Family screening of first-degree relatives must be undertaken — begin with mutation analysis if proband's mutations are known
- MRI brain: T2 hyperintensity in basal ganglia; "face of giant panda sign" in midbrain
- KF rings present in 99% with neuropsychiatric disease but only 30–50% with hepatic disease
Active Recall - Wilson's Disease Diagnosis
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (Section 7.2.2 – Wilson Disease) [2] Senior notes: Ryan Ho GI.pdf (Section 4.5.3 – Wilson's Disease) [3] Senior notes: Maksim Medicine Notes.pdf (Wilson's disease) [4] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Wilson's disease – Diagnosis) [7] Senior notes: Block A - Patients with non-viral chronic liver diseases.pdf [8] Lecture slides: Teaching Clinic - Non-viral chronic liver diseases (Prof. Yuen Man Fung) 2.pdf (Wilson's Disease – Diagnosis slide) [11] Senior notes: Block A - Gastrointestinal Data Interpretation.pdf [18] Senior notes: Ryan Ho Chemical Path.pdf (Section 8.2 – Investigations of IEM)
Management of Wilson's Disease
Wilson's disease management rests on a simple concept: copper is accumulating because the body cannot excrete it, so we must either remove the excess copper (chelation), block its absorption (zinc), or replace the defective liver (transplantation). Treatment is lifelong — discontinuation leads to relapse and can be fatal.
The management strategy depends on the clinical presentation and disease severity:
- Symptomatic patients (hepatic, neurological, or both) → copper chelation therapy to de-copper the body
- Asymptomatic patients / maintenance → zinc therapy to prevent copper re-accumulation
- Acute liver failure → rapid copper removal + consideration of liver transplantation
- Decompensated cirrhosis refractory to medical therapy → liver transplantation
- All patients → genetic counselling, family screening, dietary advice, lifelong monitoring
Pharmacological Treatment — Detailed Breakdown
There are two categories of drugs: copper chelators (remove accumulated copper) and copper absorption inhibitors (prevent further uptake from the gut).
A. Copper Chelators
The concept of chelation: "chelator" comes from the Greek word chele meaning "claw" — these drugs literally grab copper ions and form soluble complexes that can be excreted in urine.
"Penicillamine" — derived from penicillin (it is a degradation product), but it is NOT an antibiotic. The "-amine" suffix reflects its amino acid-like structure.
| Parameter | Detail |
|---|---|
| Mechanism | Chelates free copper → forms a soluble penicillamine-copper complex → excreted renally in urine |
| Indication | First-line chelator due to lower cost, but similar efficacy as trientine [3]. Symptomatic hepatic Wilson's disease; historically also used in neurological disease but trientine is now preferred for neurological presentations (see below) |
| Dose | Start at 250–500 mg/day, titrate up to 1–1.5 g/day in 2–4 divided doses. Take on an empty stomach (1 hour before or 2 hours after meals) — food reduces absorption |
| Must co-prescribe | Given with vitamin B6 (pyridoxine) [3] — penicillamine is a pyridoxine antagonist; without supplementation, patients can develop B6 deficiency (peripheral neuropathy, sideroblastic anaemia) |
| Monitoring | 24h urine copper (should initially rise with treatment, then fall as body stores deplete); ceruloplasmin; LFT; CBC; urinalysis (for proteinuria) |
Side effects — this is a high-yield exam list:
| Side Effect | Mechanism |
|---|---|
| Initial worsening of neurological symptoms | Penicillamine causes worsened neurological symptoms in the first few days — Patient is used to copper in brain, but once penicillamine is given, they lose copper, body is not used to the change, may exacerbate the neuro symptoms [7]. This is due to rapid mobilisation of hepatic copper into the bloodstream before it can be excreted → transient spike in free copper → paradoxical worsening. Occurs in up to 50% of patients with neurological disease |
| Nephrotoxicity | Immune complex deposition → membranous nephropathy → proteinuria → nephrotic syndrome. Monitor with regular urinalysis [3] |
| Myasthenia gravis (MG) | Drug-induced autoimmune phenomenon — penicillamine can induce anti-acetylcholine receptor antibodies [3] |
| Drug-induced lupus (DIL) | Penicillamine-induced autoimmune phenomenon — ANA positive, anti-histone antibodies [3] |
| Bone marrow suppression | Aplastic anaemia, thrombocytopenia, agranulocytosis — monitor CBC |
| Skin reactions | Elastosis perforans serpiginosa (abnormal elastic tissue), pemphigus, rash |
| GI upset | Nausea, anorexia — take on empty stomach |
| Taste disturbance | Dysgeusia — usually transient |
Critical Exam Point – Neurological Worsening with Penicillamine
Penicillamine causes worsened neurological symptoms in the first few days [7]. This is the single most important reason why trientine is preferred over penicillamine in patients presenting with neurological disease. The worsening can be irreversible. If you must use penicillamine, start at a very low dose and titrate slowly.
Contraindications:
- Previous penicillamine hypersensitivity
- History of penicillamine-induced aplastic anaemia or agranulocytosis
- Lupus nephritis or pre-existing renal disease (relative)
- Caution in penicillin allergy (cross-reactivity is rare but theoretically possible due to structural relationship)
"Trientine" — "tri-" = three, "en" = from ethylene, "-tine" = amine; it has three ethylene diamine groups that form a cage to trap copper.
| Parameter | Detail |
|---|---|
| Mechanism | Alternative copper chelator — chelates copper in the GI tract (reducing absorption) and in the circulation → excreted renally |
| Indication | Similar efficacy as penicillamine [3]. Preferred over penicillamine for neurological Wilson's disease because it causes less neurological worsening. Also used when penicillamine is not tolerated (side effects) |
| Dose | 750–1500 mg/day in 2–3 divided doses, on an empty stomach |
| Advantage | Fewer and less severe side effects than penicillamine; lower risk of initial neurological deterioration |
Side effects:
| Side Effect | Mechanism |
|---|---|
| Chelates iron and zinc to form ineffective complexes | Separate by 1 hour when taking iron or zinc supplements [3] — if taken together, trientine binds these metals instead of copper, reducing efficacy |
| GI upset | Less common than penicillamine |
| Sideroblastic anaemia | Due to iron chelation (rare) |
| Pancytopenia | Rare |
Contraindications:
- Known hypersensitivity
- Concurrent iron supplementation (relative — separate timing)
| Feature | Penicillamine | Trientine |
|---|---|---|
| Efficacy | Similar [3] | Similar [3] |
| Cost | Lower cost — preferred for this reason [3] | More expensive |
| Initial neuro worsening | Up to 50% — significant risk [7] | Lower risk — preferred for neurological disease |
| Must co-prescribe | Vitamin B6 [3] | No B6 needed |
| Autoimmune side effects | MG, lupus, nephrotoxicity | Much rarer |
| Drug interactions | Fewer | Chelates iron/zinc — separate by 1 hour [3] |
3. Oral Zinc (Zinc acetate, Zinc sulfate)
"Zinc" — the mechanism is beautifully logical and worth understanding from first principles.
| Parameter | Detail |
|---|---|
| Mechanism | Zinc induces metallothionein synthesis in enterocytes. Metallothionein is a cysteine-rich protein that has an extremely high affinity for copper. When metallothionein binds copper in the enterocyte, the copper becomes trapped inside the cell. When the enterocyte is naturally shed (enterocyte turnover every 3–5 days), the copper-metallothionein complex is lost in the faeces → net negative copper balance. Zinc also induces metallothionein in hepatocytes, binding intracellular copper and rendering it non-toxic |
| Indication | Maintenance treatment in asymptomatic patients [3]; also used as maintenance after initial de-coppering with a chelator; can be used in presymptomatic patients identified by family screening; suitable for pregnant patients (safer profile) |
| Dose | 150 mg elemental zinc daily in 3 divided doses (e.g., zinc acetate 50 mg TDS), taken on an empty stomach (at least 1 hour before meals) |
| NOT suitable as sole initial therapy in symptomatic patients | Too slow-acting — it takes weeks to months to build up sufficient metallothionein; meanwhile copper continues to damage organs. Use chelator first to rapidly de-copper, then switch to zinc for maintenance |
Side effects:
| Side Effect | Mechanism |
|---|---|
| GI upset | Main side effect [3] — nausea, abdominal pain, metallic taste. Zinc acetate may be better tolerated than zinc sulfate |
| Elevated lipase/amylase | Usually asymptomatic; rarely clinically significant pancreatitis |
Contraindications:
- Hypersensitivity to zinc salts
- Should NOT be taken concurrently with copper chelators (zinc induces metallothionein which would then chelate the chelator-copper complex before it can be excreted) — separate by at least 1–2 hours if used together during transition periods
Zinc – The Elegant Mechanism
Think of zinc therapy as "setting a trap in the gut." Zinc upregulates metallothionein in enterocytes → metallothionein preferentially binds dietary copper → copper is trapped in the enterocyte → when the enterocyte dies and is shed into the gut lumen (normal turnover), copper is lost in the stool. The body never absorbs the copper in the first place. This is why zinc is ideal for maintenance but too slow for acute treatment.
| Clinical Scenario | First-Line Treatment | Rationale |
|---|---|---|
| Symptomatic hepatic disease | Penicillamine (+ vitamin B6) or Trientine | Need rapid de-coppering; penicillamine preferred for cost; trientine if intolerant [3] |
| Neurological / psychiatric disease | Trientine preferred | Lower risk of initial neurological worsening than penicillamine [7] |
| Asymptomatic / presymptomatic | Oral Zinc | Maintenance treatment in asymptomatic patients [3]; prevents copper accumulation without aggressive chelation |
| Maintenance after de-coppering | Oral Zinc ± low-dose chelator | Long-term prevention of re-accumulation |
| Pregnancy | Oral Zinc | Safest profile; chelators are teratogenic (especially penicillamine — associated with cutis laxa and connective tissue defects in newborn). Dose may need to be adjusted |
| Paediatric / family screening | Oral Zinc or low-dose Trientine | Depending on age and disease status |
Non-Pharmacological Management
| Measure | Detail |
|---|---|
| Avoid high-copper foods | Shellfish (especially oysters, lobster), liver and organ meats, chocolate, nuts (especially cashews), mushrooms, soy products, dried fruits |
| Safe foods | Most vegetables, fruits, grains, rice, chicken, fish |
| Water | Check household water copper content — copper piping can leach copper into water; use bottled water if copper levels are high |
| Practical importance | Diet alone is NEVER sufficient — always requires pharmacotherapy. Dietary measures are adjunctive |
- Alcohol — direct hepatotoxin that accelerates liver damage in an already compromised organ
- Paracetamol excess — avoid high doses
- Hepatotoxic drugs — check any new medication for hepatotoxicity
- AR inheritance → 25% risk to siblings
- Carrier testing for partners of patients with Wilson's disease
- Prenatal diagnosis possible if both mutations in the family are known
Family screening of first-degree relatives must be undertaken [8]
- All siblings and children of the proband should be screened
- Screening: ceruloplasmin, 24h urine copper, LFT, slit-lamp examination
- Family screening of siblings should begin with mutation analysis for ATP7B mutation if the identified patient (proband) has been tested [4]
Management of Acute Liver Failure Due to Wilson's Disease
This is a medical emergency. The approach combines rapid copper removal with consideration for liver transplantation.
| Method | Mechanism |
|---|---|
| Haemodialysis | Rapid copper removal [3] — dialysis directly removes free copper from the circulation. Also corrects electrolyte and acid-base disturbances |
| Plasmapheresis / plasma exchange | Removes copper-containing plasma proteins and free copper; also removes inflammatory cytokines |
| Albumin dialysis (MARS — Molecular Adsorbents Recirculating System) | Experimental — removes albumin-bound toxins including copper |
Standard acute liver failure management principles apply:
- Airway protection — patients may develop hepatic encephalopathy
- Haemodynamic support — fluid resuscitation, vasopressors if needed
- Coagulopathy management — FFP / cryoprecipitate only if actively bleeding or for procedures (avoid "correcting" INR unnecessarily as it is a prognostic marker)
- Cerebral oedema monitoring — ICP monitoring in grade III/IV encephalopathy
- Infection surveillance — sepsis is a major cause of death in ALF
- Renal support — renal replacement therapy if oliguric/anuric (hepatorenal syndrome + direct copper nephrotoxicity)
- Nutrition — enteral feeding preferred; avoid protein restriction (this is outdated)
| Parameter | Detail |
|---|---|
| Why it is curative | Liver transplantation provides normal ATP7B in the graft liver [1] — the new liver has functional copper transport machinery, so copper metabolism normalises. It is essentially a form of gene therapy at the organ level |
| Indications | Indicated for fulminant hepatic failure: coagulopathy and encephalopathy, Coombs-negative haemolytic anaemia, rapid deterioration within 8 weeks from onset of illness [1][8][19] |
| Indicated for those refractory to medical therapy — i.e., decompensated cirrhosis that fails to respond to chelation [8][19] | |
| NOT indicated | Not indicated if only for neurologic disease [19] — this is explicitly stated in Prof. Yuen's lecture. The rationale: liver transplant carries significant surgical morbidity/mortality, and neurological disease can often be managed medically. However, this remains controversial (see below) |
| Prognostic scoring | New Wilson Index (Revised King's Score) — incorporates bilirubin, INR, AST, WCC, albumin. Score ≥ 11 predicts death without transplant |
GC High Yield – Prof. Yuen's Lecture Points on Treatment
Treatment of Wilson's Disease:
- Liver transplantation — effective cure
- Indicated for fulminant hepatic failure:
- Coagulopathy and encephalopathy
- Coombs-negative haemolytic anaemia
- Rapid deterioration within 8 weeks from onset of illness
- Indicated for those refractory to medical therapy
- Not indicated if only for neurologic disease [19]
These are directly from the GC teaching clinic lecture slide and represent expected exam content.
- The standard teaching is not indicated if only for neurologic disease [19]
- However, emerging evidence suggests that liver transplant can improve and even reverse neurological symptoms in some patients, because normalisation of copper metabolism prevents ongoing brain deposition
- Liver transplantation has been demonstrated to improve neurological symptomatology and can act as a form of gene therapy [1]
- Current consensus (EASL 2012/AASLD 2022 guidelines): liver transplantation is NOT recommended solely for neurological disease, but may be considered in selected cases where neurological disease is severe and refractory to medical chelation therapy
- This is an evolving area — for exam purposes, state the standard teaching first, then mention the controversy
| Parameter | Frequency | Purpose |
|---|---|---|
| 24h urinary copper | Every 3–6 months initially, then annually | Assess de-coppering progress; on chelation, expect initial rise then gradual fall; on zinc, should remain < 75 μg/day |
| Serum ceruloplasmin | Every 6–12 months | Baseline marker; may rise slightly with treatment |
| Free (non-CP-bound) copper | Every 3–6 months | Target < 15 μg/dL on maintenance |
| LFT | Every 3–6 months | Monitor liver disease activity; assess response |
| CBC | Every 1–3 months (penicillamine); less frequent (trientine/zinc) | Monitor for bone marrow suppression (penicillamine) |
| Urinalysis | Every 1–3 months (penicillamine) | Monitor for proteinuria (nephrotoxicity) |
| Slit-lamp exam | Annually | KF rings should fade with effective treatment |
| Clinical neurological assessment | Every visit | Detect improvement or deterioration |
| Compliance assessment | Every visit | Non-compliance is a major cause of treatment failure and can be fatal |
Non-Compliance = Death
Non-compliance with chelation/zinc therapy is the single most dangerous pitfall. Patients who stop treatment — even after years of stability — will re-accumulate copper and can develop rapidly progressive liver failure or neurological deterioration that may be irreversible. Prognosis is excellent if treated: 86% 5-year survival; ~30% die from hepatic complications if untreated [1]. Adolescents are particularly at risk for non-compliance.
| Scenario | Outcome |
|---|---|
| Treated, compliant | Excellent: 86% 5-year survival [1]; normal life expectancy is achievable |
| Untreated | Universally fatal; ~30% die from hepatic complications [1] |
| Post-transplant | > 80% 5-year survival; copper metabolism normalises; KF rings fade |
| Neurological disease | Hepatic symptoms respond faster than neurological symptoms; neurological improvement may take months to years and may be incomplete in advanced disease |
| Treatment | Mechanism | Indication | Key Side Effects | Key Points |
|---|---|---|---|---|
| Penicillamine | Cu chelation → renal excretion | Symptomatic hepatic disease; 1st-line by cost | Initial neuro worsening, nephrotoxicity, MG, DIL [3] | Give with vitamin B6 [3] |
| Trientine | Cu chelation → renal excretion | Neurological disease; penicillamine-intolerant | Chelates iron/zinc [3]; GI upset | Separate from Fe/Zn by 1 hour [3] |
| Oral Zinc | Induces metallothionein → blocks gut Cu absorption | Maintenance in asymptomatic patients [3]; pregnancy | GI upset [3] | Too slow for initial Rx of symptomatic disease |
| Haemodialysis | Rapid Cu removal [3] | Acute liver failure | Standard dialysis risks | Bridge to transplant |
| Liver transplant | Effective cure — provides normal ATP7B [1][19] | Fulminant liver failure; refractory decompensated cirrhosis [19] | Surgical and immunosuppression risks | Not indicated if only for neurologic disease [19] |
High Yield Summary – Management
- Treatment is lifelong — discontinuation leads to relapse and death
- Symptomatic patients → copper chelator (penicillamine or trientine) for initial de-coppering
- Penicillamine: lower cost, preferred first-line; co-prescribe vitamin B6; S/E include initial neurological worsening, nephrotoxicity, MG, drug-induced lupus [3][7]
- Trientine: preferred for neurological disease because penicillamine causes initial worsening; chelates iron/zinc → separate by 1 hour [3]
- Oral Zinc: maintenance treatment in asymptomatic patients [3]; mechanism = induces metallothionein in enterocytes
- Liver transplantation = effective cure; indicated for fulminant hepatic failure (coagulopathy + encephalopathy + Coombs-negative haemolysis + rapid deterioration within 8 weeks) and refractory decompensated cirrhosis [19]
- Liver transplantation NOT indicated if only for neurologic disease [19]
- Haemodialysis for rapid copper removal in acute liver failure [3]
- Genetic counselling and family screening of first-degree relatives are mandatory [3][8]
- Prognosis: excellent if treated (86% 5-year survival); universally fatal if untreated [1]
Active Recall - Wilson's Disease Management
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (Section 7.2.2 – Wilson Disease, Management) [3] Senior notes: Maksim Medicine Notes.pdf (Wilson's disease – Management) [4] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Wilson's disease – Diagnosis and Family Screening) [7] Senior notes: Block A - Patients with non-viral chronic liver diseases.pdf [8] Lecture slides: Teaching Clinic - Non-viral chronic liver diseases (Prof. Yuen Man Fung) 2.pdf (Wilson's Disease – Diagnosis slide) [19] Lecture slides: Teaching Clinic - Non-viral chronic liver diseases (Prof. Yuen Man Fung) 2.pdf (Wilson's Disease – Treatment slide)
Complications of Wilson's Disease
The complications of Wilson's disease arise from two fundamental processes:
- Direct copper toxicity to the organs where copper accumulates (liver, brain, kidneys, blood, eyes, joints, heart)
- Secondary consequences of end-organ damage, particularly the complications of liver cirrhosis and portal hypertension — these are shared with cirrhosis of any cause but deserve specific attention because they are the leading cause of morbidity and mortality in Wilson's disease
Additionally, there are treatment-related complications that are important to recognise.
Prognosis: excellent if treated, 86% 5-year survival; ~30% die from hepatic complications if untreated [1]
A. Hepatic Complications
Wilson's disease progresses through a spectrum of liver injury. Once cirrhosis develops, the patient faces all of the complications of cirrhosis — identical to cirrhosis from any aetiology.
GC High Yield – Complications of Cirrhosis (One-Slide Overview)
From the GC 026 lecture slide on cirrhosis [20], the complications framework is:
Compensated cirrhosis (Child A):
- Variceal disease
- Portal vein thrombosis
- HCC
Decompensated cirrhosis (Child B/C):
- Variceal disease
- Portal vein thrombosis
- Ascites
- SBP
- Hepatic hydrothorax
- Hepatorenal syndrome
Other complications (both):
- HE (hepatic encephalopathy)
- HCC
- Liver failure
- Infections
- Bleeding tendency
This framework applies to Wilson's disease-related cirrhosis just as it does to any other cause.
| Aspect | Detail |
|---|---|
| Frequency | Occurs in 8–12% of Wilson's disease patients [1] |
| Mechanism | Massive hepatocyte necrosis from copper overload → sudden release of large quantities of stored copper into the bloodstream → multi-organ toxicity |
| Key features | Coagulopathy and encephalopathy, Coombs-negative haemolytic anaemia, rapid deterioration within 8 weeks from onset of illness [1][19] |
| Why haemolysis occurs | The massive copper release deposits on RBC membranes → oxidative damage → intravascular haemolysis (Coombs-negative because it is not immune-mediated) |
| Paradoxically low ALP | ALP is a zinc-dependent metalloenzyme; excess copper displaces zinc → reduced enzyme activity |
| Prognosis without transplant | Near-universally fatal; New Wilson Index ≥ 11 predicts death without transplant |
| Management | Rapid copper removal (haemodialysis, plasmapheresis) → liver transplantation if criteria met [1][19] |
Fulminant hepatic failure due to Wilson's has a very specific feature: young patients with no reason for fulminant liver failure, exclusion of all other common causes → only finding is low haemoglobin → Coombs-negative haemolytic anaemia [7]
2. Cirrhosis and Portal Hypertension
Present in ~35–45% of patients at time of diagnosis [1]. Once cirrhosis is established, all portal hypertension-related complications ensue. Let me walk through each:
| Aspect | Detail |
|---|---|
| Mechanism | Portal hypertension (pressure > 10 mmHg in portal system) → blood seeks alternative routes (portosystemic anastomoses) → oesophageal and gastric varices develop → thin-walled veins under high pressure → rupture → massive upper GI haemorrhage |
| Presentation | Haematemesis (coffee-ground or frank blood), melaena, haemodynamic instability |
| Why it matters | Life-threatening; mortality per episode ~15–20% |
| Management | Resuscitation, IV octreotide/terlipressin, urgent OGD with band ligation, secondary prophylaxis with non-selective beta-blockers |
| Aspect | Detail |
|---|---|
| Mechanism | Portal hypertension → ↑ splanchnic hydrostatic pressure + arterial vasodilation → activation of RAAS and sympathetic nervous system → Na⁺/water retention. Combined with ↓ albumin (impaired hepatic synthesis) → ↓ plasma oncotic pressure → fluid transudation into peritoneal cavity |
| Clinical sign | Shifting dullness, fluid thrill; USS for small volumes |
| Management | Salt restriction, diuretics (spironolactone ± furosemide), therapeutic paracentesis with albumin replacement |
| Aspect | Detail |
|---|---|
| Mechanism | Bacterial translocation from gut to ascitic fluid (impaired gut barrier + portal hypertension) + reduced opsonic activity of ascitic fluid (low complement, low protein) + impaired reticuloendothelial function in liver failure → infection of ascitic fluid without obvious intra-abdominal source |
| Presentation | Fever, abdominal pain, worsening ascites, encephalopathy; can be insidious |
| Diagnosis | Ascitic fluid PMN > 250/mm³ |
| Management | IV third-generation cephalosporin (e.g. ceftriaxone); secondary prophylaxis with oral norfloxacin/ciprofloxacin |
| Aspect | Detail |
|---|---|
| Mechanism | Ascitic fluid tracks through diaphragmatic defects (usually right-sided) into the pleural space |
| Presentation | Dyspnoea, right-sided pleural effusion in a cirrhotic patient without primary cardiopulmonary disease |
| Aspect | Detail |
|---|---|
| Mechanism | Severe portal hypertension → splanchnic vasodilation → effective hypovolaemia → maximal RAAS/sympathetic activation → profound renal vasoconstriction → functional renal failure (kidneys are structurally normal) |
| Types | Type 1 (rapidly progressive, doubling of creatinine in < 2 weeks) and Type 2 (more gradual, a/w refractory ascites) |
| Key point | HRS in Wilson's disease can be compounded by direct copper nephrotoxicity |
| Management | Terlipressin + albumin; definitive treatment is liver transplantation |
| Aspect | Detail |
|---|---|
| Mechanism | Sluggish portal flow in cirrhosis + endothelial damage + hypercoagulable tendency (paradoxically, despite coagulopathy, cirrhotic patients have a "rebalanced" haemostasis with thrombotic risk) |
| Consequence | Worsens portal hypertension; can precipitate variceal bleeding |
| Aspect | Detail |
|---|---|
| Mechanism | Cirrhosis from any cause → chronic hepatocyte injury and regeneration → accumulation of somatic mutations → dysplastic nodules → HCC |
| Risk in Wilson's | Any cause of cirrhosis is a risk factor for HCC, including Wilson's disease [13]. However, the risk of HCC in Wilson's disease is lower than in viral hepatitis-related cirrhosis. The reason is debated — copper may have some anti-proliferative effects, and effective chelation therapy reduces liver damage |
| Surveillance | All Wilson's disease patients with cirrhosis should undergo 6-monthly USS ± AFP for HCC screening |
| Aspect | Detail |
|---|---|
| Mechanism | Liver failure → impaired hepatic clearance of ammonia and other neurotoxins → these reach the brain via portosystemic shunting → astrocyte swelling (Alzheimer type II astrocytosis) → cerebral oedema and functional impairment |
| Precipitants | GI bleeding (gut bacteria convert blood proteins to ammonia), constipation (prolonged ammonia absorption), infection/sepsis, electrolyte disturbances (hypokalaemia, hyponatraemia), dehydration, sedatives, dietary protein excess (now largely disproven as a major factor) [5] |
| Grading | West Haven criteria: Grade I (sleep disturbance, shortened attention) → Grade IV (coma) |
| Management | Lactulose (osmotic laxative — ↓ gut transit time → ↓ ammonia absorption; also acidifies colonic lumen → converts NH₃ to NH₄⁺ which cannot cross membranes), rifaximin (non-absorbable antibiotic — reduces ammonia-producing gut bacteria), treat precipitants |
Wilson's – Double Encephalopathy
Wilson's disease patients can develop encephalopathy from TWO separate mechanisms: (1) hepatic encephalopathy from liver failure (ammonia-mediated), and (2) copper encephalopathy from direct copper toxicity to the brain (basal ganglia, cerebellum). These are mechanistically distinct and may coexist. Hepatic encephalopathy is typically fluctuating and reversible; copper-related neurological damage may be progressive and less reversible.
| Aspect | Detail |
|---|---|
| Mechanism | Liver failure → ↓ synthesis of clotting factors (II, VII, IX, X — all made in the liver) + ↓ thrombopoietin → thrombocytopenia is compounded by hypersplenism from portal hypertension + impaired clearance of fibrinolytic factors |
| Clinical consequence | Easy bruising, prolonged bleeding from minor wounds, risk of catastrophic haemorrhage from varices or procedures |
| Aspect | Detail |
|---|---|
| Mechanism | Reticuloendothelial dysfunction and reduced opsonisation [5] — the liver's Kupffer cells (resident macrophages) are functionally impaired → cannot clear bacteria from the portal circulation. Impaired hepatic synthetic function → reduced complement and opsonin production. Gut bacterial translocation is enhanced |
| Common organisms | Bacteria — especially from the respiratory and urinary tract; Staph, Strep, gram-negative rods; bacteraemia in up to 25% of fulminant hepatic failure patients. Fungal infection — especially Candida [5] |
| Clinical importance | Sepsis is a major cause of death in liver failure; have a low threshold for blood cultures and empirical antibiotics |
These arise from progressive copper deposition in the brain and can occur as the presenting feature or as a complication of ongoing disease.
| Complication | Mechanism | Detail |
|---|---|---|
| Irreversible neurological damage | Prolonged copper deposition → neuronal death, demyelination, gliosis | If treatment is delayed or the patient is non-compliant, neurological deficits (dystonia, dysarthria, ataxia) may become permanent. Early treatment is critical |
| Pseudobulbar palsy | Bilateral UMN lesions from copper deposition in brainstem | Dysphagia → risk of aspiration pneumonia (a common cause of morbidity and mortality in neurological Wilson's disease) |
| Seizures | Cortical copper deposition → neuronal hyperexcitability | Occur in a minority of patients; require anticonvulsant management |
| Psychiatric decompensation | Copper in cortex and limbic system | Depression, psychosis, personality change — can lead to social dysfunction, non-compliance with treatment, and suicide risk |
| Treatment-related neurological worsening | Penicillamine causes worsened neurological symptoms in the first few days — patient is used to copper in brain, but once penicillamine is given, they lose copper, body is not used, may exacerbate the neuro symptoms [7] | Can be irreversible; this is why trientine is preferred for neurological disease |
| Complication | Mechanism |
|---|---|
| Coombs-negative haemolytic anaemia | Associated with acute liver failure but can occur episodically independent of liver failure. Results from effects of excess copper ions on the RBC membrane due to hepatic copper release following cellular necrosis [4] |
| Severe anaemia | Combination of haemolysis + nutritional deficiency (folate consumption from chronic haemolysis) + possible bone marrow suppression from copper toxicity |
| Thrombocytopenia | Hypersplenism from portal hypertension; also possible direct copper marrow toxicity |
| Gallstones (pigment stones) | Chronic haemolysis → increased unconjugated bilirubin → pigment gallstone formation → biliary colic, cholecystitis, choledocholithiasis |
| Complication | Mechanism |
|---|---|
| Fanconi syndrome | Copper deposition in proximal tubule → generalised proximal tubular transport defect → aminoaciduria, glycosuria, phosphaturia, uricosuria, bicarbonaturia (type 2 RTA) |
| Nephrolithiasis | Hypercalciuria and hyperuricosuria from tubular dysfunction promote stone formation |
| Renal tubular acidosis (Type 2) | Bicarbonate wasting → normal anion gap metabolic acidosis |
| Osteoporosis / Rickets / Osteomalacia | Phosphate wasting (phosphaturia from Fanconi syndrome) → hypophosphataemia → impaired bone mineralisation. Also vitamin D activation may be impaired |
| Hepatorenal syndrome | See above — in the setting of decompensated cirrhosis |
| Complication | Detail |
|---|---|
| Kayser-Fleischer rings | While considered a diagnostic sign, they also represent tissue damage. They fade with effective treatment, which can be used to monitor response |
| Sunflower cataracts | Copper deposition in the lens — usually does not significantly impair vision, but can contribute to visual symptoms in some patients |
| Complication | Mechanism |
|---|---|
| Premature osteoarthritis | Copper deposition in articular cartilage → chondrocyte damage and degradation |
| Chondrocalcinosis / CPPD disease | Wilson's is a recognised metabolic cause of CPPD crystal deposition; can cause pseudogout attacks |
| Osteoporosis and pathological fractures | Multi-factorial: Fanconi syndrome (phosphate wasting), chronic liver disease (impaired vitamin D activation, reduced sex hormones), possible direct copper effect on osteoblasts |
| Complication | Mechanism |
|---|---|
| Cardiomyopathy | Copper deposition in the myocardium → dilated or hypertrophic cardiomyopathy (rare but described) |
| Arrhythmias | Copper-induced electrical instability; can also arise from electrolyte disturbances secondary to Fanconi syndrome |
| Sudden cardiac death | Very rare; from severe cardiomyopathy or arrhythmia |
These are iatrogenic complications that arise from the medications used to treat Wilson's disease.
| Complication | Drug | Mechanism |
|---|---|---|
| Initial neurological worsening | Penicillamine | Rapid mobilisation of hepatic copper → transient spike in free copper → paradoxical worsening [7]. Can be irreversible. Prevented by starting at low dose and titrating slowly, or by using trientine instead |
| Nephrotoxicity (membranous nephropathy) | Penicillamine | Immune complex deposition in glomerular basement membrane → proteinuria → nephrotic syndrome |
| Drug-induced myasthenia gravis | Penicillamine | Induction of anti-acetylcholine receptor antibodies |
| Drug-induced lupus | Penicillamine | Induction of ANA and anti-histone antibodies → lupus-like syndrome |
| Bone marrow suppression | Penicillamine | Aplastic anaemia, agranulocytosis — potentially fatal |
| Iron/zinc deficiency | Trientine | Chelates iron and zinc → if taken concurrently, forms ineffective complexes |
| GI upset | Zinc | Nausea, dyspepsia — the most common adverse effect of zinc therapy |
| Non-compliance | All | Arguably the most dangerous complication of all — adolescent patients are at highest risk. Discontinuation of therapy can lead to rapid reaccumulation of copper, fulminant liver failure, and death |
| Scenario | Outcome |
|---|---|
| Never treated | Universally fatal; majority die from liver failure [1] |
| Treatment discontinued | Rapid copper reaccumulation → can present as fulminant liver failure, acute haemolysis, or rapid neurological deterioration — often irreversible |
| Late diagnosis | Advanced cirrhosis or irreversible neurological damage already present → limited benefit from chelation alone → may require liver transplantation |
| System | Complications | Key Mechanism |
|---|---|---|
| Liver | Acute liver failure, cirrhosis, portal hypertension (varices, ascites, SBP, HRS, hepatic hydrothorax, PVT), HCC, HE, coagulopathy | Direct copper toxicity → hepatocyte damage → fibrosis → cirrhosis → portal hypertension |
| Neurological | Irreversible movement disorder, pseudobulbar palsy, aspiration pneumonia, seizures, psychiatric decompensation | Copper deposition in basal ganglia, cerebellum, cortex |
| Haematological | Coombs-negative haemolytic anaemia, thrombocytopenia, pigment gallstones | Copper toxicity to RBCs; hypersplenism; haemolysis by-products |
| Renal | Fanconi syndrome, RTA, nephrolithiasis, osteoporosis, HRS | Copper deposition in proximal tubules; decompensated cirrhosis |
| Ophthalmological | KF rings, sunflower cataracts | Copper deposition in Descemet's membrane and lens |
| MSK | Premature OA, chondrocalcinosis, osteoporosis, fractures | Copper in cartilage; Fanconi phosphaturia |
| Cardiac | Cardiomyopathy, arrhythmias | Copper deposition in myocardium |
| Treatment-related | Neurological worsening, nephrotoxicity, MG, lupus, marrow suppression, GI upset | Drug-specific mechanisms (penicillamine, trientine, zinc) |
High Yield Summary – Complications
- Hepatic complications dominate — ~30% die from hepatic complications if untreated [1]; cirrhosis is present in 35–45% at diagnosis
- Complications of cirrhosis follow the standard framework: variceal bleeding, ascites, SBP, HRS, hepatic hydrothorax, PVT, HE, HCC, coagulopathy, infections [20]
- Fulminant liver failure (8–12%) has the specific triad: Coombs-negative haemolysis + low ALP + AST:ALT > 2
- Coombs-negative haemolytic anaemia can occur with ALF or episodically independent of liver failure [4]
- Neurological complications can be irreversible if treatment is delayed — early diagnosis is critical
- Penicillamine-induced neurological worsening is a major treatment complication [7] — reason to prefer trientine in neurological disease
- Fanconi syndrome causes a cascade of renal, metabolic and skeletal complications (RTA, nephrolithiasis, osteoporosis)
- HCC risk exists in Wilson's cirrhosis — surveillance with 6-monthly USS ± AFP is required [13]
- Non-compliance is the most dangerous modifiable complication — discontinuation of lifelong treatment can be fatal
- Liver transplantation is curative and is indicated for fulminant liver failure and refractory decompensated cirrhosis [19]
Active Recall - Wilson's Disease Complications
References
[1] Senior notes: Adrian Lui Pediatrics Notes.pdf (Section 7.2.2 – Wilson Disease, Prognosis and Management) [4] Senior notes: MBBS Final MB (Medicine) (Felix PY Lai).pdf (Wilson's disease – Biochemical tests, Coombs-negative haemolytic anaemia) [5] Senior notes: Block A - A jaundiced and incoherent patient_ liver failure.pdf (Complications of liver failure, Infections) [7] Senior notes: Block A - Patients with non-viral chronic liver diseases.pdf (Wilson's – penicillamine neurological worsening, fulminant features) [13] Senior notes: Maksim Surgery Notes.pdf (Hepatocellular carcinoma – risk factors including Wilson's disease) [19] Lecture slides: Teaching Clinic - Non-viral chronic liver diseases (Prof. Yuen Man Fung) 2.pdf (Wilson's Disease – Treatment slide) [20] Lecture slides: GC 026. Abdominal distension_ascites and cirrhosis.pdf (The Cirrhotic Patient: One-Slide Overview)
High Yield Summary
- Wilson's disease = AR mutation in ATP7B gene on chromosome 13 → defective copper-transporting P-type ATPase
- Two key functional losses: failure to incorporate copper into ceruloplasmin + failure to excrete copper into bile
- Copper accumulates in liver first (from birth) → hepatocyte damage → copper spills into blood → deposits in brain, cornea, kidneys, RBCs
- Children present with hepatic disease; older patients with neurological/psychiatric disease
- KF rings (Descemet's membrane) present in 99% with neuropsychiatric and 30–50% with hepatic disease
- Coombs-negative haemolytic anaemia is the hallmark haematological manifestation — non-immune, direct copper toxicity to RBCs
- Fulminant liver failure + Coombs-negative haemolytic anaemia + low ALP in a young patient = think Wilson's
- Most patients are compound heterozygotes; > 200 mutations identified
- Universally fatal if untreated
- Genetic test does not have to be positive to diagnose — clinical + biochemical diagnosis is sufficient given the genetic heterogeneity
- Wilson's disease is a recognised metabolic cause of CPPD crystal deposition disease
- Can mimic Parkinson's disease — always check copper studies in young-onset parkinsonism
High Yield Summary – Differential Diagnosis
- Hepatic DDx: Viral hepatitis (especially HBV in HK), AIH, NAFLD, DILI, haemochromatosis, A1AT deficiency — all can cause chronic liver disease in young patients. Wilson's is distinguished by low ceruloplasmin, elevated urine copper, KF rings.
- Neurological DDx: IPD, drug-induced parkinsonism, Huntington's, NBIA — Wilson's presents younger and has systemic features (liver disease, KF rings). Always check copper studies in young-onset movement disorders.
- Haematological DDx: All causes of Coombs-negative haemolytic anaemia — Wilson's is distinguished by coexisting liver disease and copper metabolic derangement.
- ALF DDx: Viral, paracetamol, AIH — Wilson's ALF has the classic triad: Coombs-negative haemolysis + low ALP + AST:ALT > 2.
- Psychiatric DDx: Always investigate organic causes in young patients with new psychiatric symptoms — Wilson's is treatable.
- No single test is diagnostic — use the Leipzig scoring system incorporating multiple parameters.
- Family screening of first-degree relatives must be undertaken once a proband is identified.
High Yield Summary – Diagnosis
- No single test is diagnostic — use the Leipzig scoring system (≥ 4 = diagnosed)
- Three core screening tests: ceruloplasmin (< 20 mg/dL), 24h urine copper (> 100 μg), slit-lamp for KF rings
- Liver biopsy is the GOLD standard — hepatic Cu ≥ 250 μg/g dry weight is diagnostic, < 50 excludes
- Histology mimics AIH and NASH — always request quantitative copper alongside histology
- ATP7B genetic testing is NOT used for initial diagnosis due to genetic heterogeneity; reserved for unclear cases and family screening
- AST > ALT (ratio > 2) is a characteristic LFT pattern; low ALP is a clue in fulminant Wilson's
- Fulminant Wilson's ALF clues: Coombs-negative haemolysis + ALP:bilirubin < 4 + AST:ALT > 2.2
- Family screening of first-degree relatives must be undertaken — begin with mutation analysis if proband's mutations are known
- MRI brain: T2 hyperintensity in basal ganglia; "face of giant panda sign" in midbrain
- KF rings present in 99% with neuropsychiatric disease but only 30–50% with hepatic disease
High Yield Summary – Management
- Treatment is lifelong — discontinuation leads to relapse and death
- Symptomatic patients → copper chelator (penicillamine or trientine) for initial de-coppering
- Penicillamine: lower cost, preferred first-line; co-prescribe vitamin B6; S/E include initial neurological worsening, nephrotoxicity, MG, drug-induced lupus [3][7]
- Trientine: preferred for neurological disease because penicillamine causes initial worsening; chelates iron/zinc → separate by 1 hour [3]
- Oral Zinc: maintenance treatment in asymptomatic patients [3]; mechanism = induces metallothionein in enterocytes
- Liver transplantation = effective cure; indicated for fulminant hepatic failure (coagulopathy + encephalopathy + Coombs-negative haemolysis + rapid deterioration within 8 weeks) and refractory decompensated cirrhosis [19]
- Liver transplantation NOT indicated if only for neurologic disease [19]
- Haemodialysis for rapid copper removal in acute liver failure [3]
- Genetic counselling and family screening of first-degree relatives are mandatory [3][8]
- Prognosis: excellent if treated (86% 5-year survival); universally fatal if untreated [1]
High Yield Summary – Complications
- Hepatic complications dominate — ~30% die from hepatic complications if untreated [1]; cirrhosis is present in 35–45% at diagnosis
- Complications of cirrhosis follow the standard framework: variceal bleeding, ascites, SBP, HRS, hepatic hydrothorax, PVT, HE, HCC, coagulopathy, infections [20]
- Fulminant liver failure (8–12%) has the specific triad: Coombs-negative haemolysis + low ALP + AST:ALT > 2
- Coombs-negative haemolytic anaemia can occur with ALF or episodically independent of liver failure [4]
- Neurological complications can be irreversible if treatment is delayed — early diagnosis is critical
- Penicillamine-induced neurological worsening is a major treatment complication [7] — reason to prefer trientine in neurological disease
- Fanconi syndrome causes a cascade of renal, metabolic and skeletal complications (RTA, nephrolithiasis, osteoporosis)
- HCC risk exists in Wilson's cirrhosis — surveillance with 6-monthly USS ± AFP is required [13]
- Non-compliance is the most dangerous modifiable complication — discontinuation of lifelong treatment can be fatal
- Liver transplantation is curative and is indicated for fulminant liver failure and refractory decompensated cirrhosis [19]